General Biotech

March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and autoimmune applications, alongside advancements in targeted protein degradation.

ADLM 2025 was held in Chicago, IL, USA, from July 27-31. The Association for Diagnostics & Laboratory Medicine event hosted global leaders in clinical chemistry, molecular diagnostics, mass spectrometry, translational medicine, lab management, and other areas of breaking science in laboratory me

Benchmark Positive Antibodies ensure reliable validation. Biointron explains their role in confirming assay accuracy and building trust in experimental results.

FcRn is critical for IgG recycling and half-life extension. Biointron explores its biology and applications in designing durable therapeutic antibodies.

Clear intellectual property policies foster biotech growth. Biointron shows how no-royalty models encourage innovation, collaboration, and therapeutic progress.

Discover how phage display technology enables high-throughput screening of antibodies, peptides, and therapeutic proteins to accelerate drug discovery and protein engineering.

In vivo and in vitro models each shape antibody discovery differently. Biointron compares their roles in research and development to guide better therapeutic strategies.

Microfluidic technology is transforming biotechnology. Biointron shows how microfluidics enhance antibody research with precision, speed, and innovative applications.

Learn about dilution buffers in antibody research, their composition, and applications in ELISA, Western blotting, and immunohistochemistry for reliable results.

Learn the difference between ADC biosimilars as cost-effective alternatives to reference drugs and ADC isotypes engineered for distinct therapeutic properties in cancer treatment.

ADCs enhance in vivo research precision. Biointron explores how targeted payload delivery improves study accuracy and supports next-generation therapeutic design.

Research-use-only biologics support early discovery. Biointron explains how RUO materials empower preclinical antibody development and accelerate translational progress.